HHighlight Therapeutics — Series A (estimated) · €22.6M
Highlight Therapeutics, formerly Bioncotech, is a clinical-stage biotech. It closed €22.6M co-led by Columbus Venture Partners' Life Science Fund II and Advent Life Sciences, with CDTI (via Innvierte, €3.6M) and existing shareholders also investing. The money funds Phase 2 combination trials of its RNA-based drug BO-112. No series name was given.
LeadColumbus Venture Partners, Advent Life Sciences
RoundSeries A (estimated)
Announced3 Feb 2021
CityValencia
SectorHealthtech & Bio · Biotech / Immuno-oncology
Source
V
V
